secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dare Bioscience, Inc. (DARE)
CIK:        0001401914
Form:       8-K
Filed at:   2023-03-30T23:59:59+00:00
Accession:  0001493152-23-009600
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dare Bioscience reports FY2022 cash $34.7M; XACIATO first commercial sale expected Q2 2023
--------------------------------------------------------------------------------

- Cash and cash equivalents $34.7M at Dec 31, 2022, down from $51.7M at Dec 31, 2021.
- G&A expenses $11.2M (FY2022) vs $8.4M (FY2021); R&D expenses $30.0M vs $30.6M.
- Received $24.1M in non-dilutive funding in 2022: $10M from Organon license, $13.3M grants, $0.8M Australian rebate.
- XACIATO first commercial sale expected Q2 2023, triggering $2.5M milestone to Dare.
- Sildenafil Cream Phase 2b topline data targeted for Q2 2023; Ovaprene pivotal study initiation mid-2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401914/000149315223009600/0001493152-23-009600-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401914/000149315223009600/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-009600

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer